Live
Home·Deals·biopharmaceutical·ING acquires Halozyme Therapeutics
ING acquires Halozyme Therapeutics (2026)
SEO URLwww.firestrike.ai/deals/halozyme-therapeutics-ing-acquisition-2026
acquisitionAnnounced · Feb 13, 2026biopharmaceuticalSource · CredibleArticle · Factual
Halozyme Therapeutics
ING
Halozyme Therapeutics · ING

ING acquires Halozyme Therapeutics

David Najork
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
ShareXLinkedInEmail
Deal value
$6.65M
Target
Halozyme Therapeutics
Halozyme Therapeutics
NASDAQ: HALO · San Diego, California
Acquirer
ING
ING
Financial Stake
Status
Completed

ING agreed to acquire Halozyme Therapeutics. Reported deal value: $6.65M. Status: Completed. Sector: biopharmaceutical. Target headquarters context: San Diego, California, United States.

This page summarizes publicly available information about the transaction as of 2026-02-13. Figures and status may change as filings and press coverage update.

ING Groep NV Acquires New Stake in Halozyme Therapeutics , Inc. $HALO

Deal timeline

Announced
Feb 13, 2026 · marketbeat.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context

This transaction is classified in biopharmaceutical with a reported deal value of $6.65M. Figures and status may change as sources update.

Sources: marketbeat.com · Primary article · FireStrike proprietary index